Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies
Pharmaceutical Technology
MARCH 28, 2023
The system comprises the Cas9 enzyme and a guide RNA. Vertex Pharmaceuticals Cell and Genetic Therapies chief and executive vice-president Bastiano Sanna said: “We have multiple programmes in our T1D portfolio including VX-880 and VX-264, which are in the clinic, as well as our hypoimmune programme, in preclinical development.
Let's personalize your content